Rangering i aksjer
#27062
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Aksjekurs
$2.04
Sist synkronisert: 2025-12-09
Handel Mural Oncology plc (MURA)
Pris MURA pris med markedsverdi på B
Markedsverdi av Mural Oncology plc(MURA)
Markedsverdi: $35.38M
Per August 2026 har Mural Oncology plc en markedsverdi på $35.38M. Dette gjør Mural Oncology plc til det 27062nd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Mural Oncology plc fra 2023 til 2026
MURA sammenlignet med topp 5 mest populære stocks
| Pris på MURA |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.301T
|
+14,980,430.71%
|
|
|
|
|
$4.634T
|
+13,095,454.05%
|
|
|
|
|
$4.143T
|
+11,708,180.82%
|
|
|
|
|
$3.589T
|
+10,143,655.51%
|
|
|
|
|
$2.857T
|
+8,073,786.56%
|
